- Home
- NYT vs EXEL Comparison
NYT vs EXEL Comparison
Compare NYT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NYT | EXEL |
|---|---|---|
| Founded | 1851 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 11.4B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NYT | EXEL |
|---|---|---|
| Price | $79.12 | $44.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 21 |
| Target Price | ★ $72.14 | $46.50 |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | 18.08 | ★ 57.95 |
| EPS | 2.09 | ★ 2.78 |
| Revenue | ★ $1,783,639,000.00 | $452,477,000.00 |
| Revenue This Year | $10.58 | $13.61 |
| Revenue Next Year | $6.98 | $13.13 |
| P/E Ratio | $37.90 | ★ $16.05 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.03 | $33.76 |
| 52 Week High | $87.10 | $48.74 |
Technical Indicators
Market Signals| Indicator | NYT | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 50.94 |
| Support Level | $76.84 | $40.98 |
| Resistance Level | $82.49 | $46.66 |
| Average True Range (ATR) | 2.12 | 1.37 |
| MACD | -0.33 | -0.13 |
| Stochastic Oscillator | 52.76 | 23.86 |
Price Performance
Historical ComparisonAbout NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.